SALT LAKE CITY, UT–(Marketwire – May 8, 2009) – 4Life Research™ announced today the completion of a new preliminary scientific test showing the effect of 4Life Transfer Factor Tri-Factor® Formula on IgA antibody production. Participants took 4Life Transfer Factor Tri-Factor Formula for two weeks, followed by 4Life Transfer Factor RioVida® Tri-Factor Formula for another two weeks. One hundred percent of participants saw an increase in the production rate of salivary secretory IgA when compared to a one-week baseline, with an average increase of 73%.
IgA antibodies, produced by plasma cells, are highly specific proteins used by the immune system to bind and neutralize foreign invaders. IgA bathes the surface of the mucous membranes. These y-shaped proteins bind to invaders, preventing them from attaching and passing through the mucous lining into the tissues and bloodstream of the body.
The test was conducted by 4Life Chief Executive Officer David Lisonbee; Chief Scientific Officer Calvin McCausland, Ph.D.; Health Sciences Advisory Board Member Richard Bennett, Ph.D.; Director of Health Information Services Brent Vaughan; and Research Scientist Shane Lefler.
“I’m proud to be associated with a company that values scientific research so highly,” commented McCausland. “It’s wonderful to provide effective immune system support products that are also backed up by sound scientific studies.”
“I continue to be amazed at 4Life Transfer Factor’s ability to boost and support the immune system,” said Bennett. “This preliminary IgA test suggests another layer of vital immune system protection that 4Life Transfer Factor provides.”
“4Life’s Research and Development team has identified that 4Life Transfer Factor can support another vital component of a healthy immune system — IgA antibodies — once again proving our commitment to stay at the forefront of immune system science,” remarked Lisonbee.
4Life, category creator of Transferceutical™ Science and world leader in the development, production, and distribution of Transfer Factor support products, continues to post growth in more than 40 countries around the world.
I just read a disturbing article in the New York Times about recent reports of deaths and abnormal behaviour in Japanese children who were given the anti-influenza drug Tamiflu.
Here is a summary of the key points I learned from this article:
1. Tamiflu was approved for use in the United States in 1999, and in Japan in late 2000.
2. According to Roche, the manufacturer of Tamiflu, of the 13 million prescriptions written for children worldwide, 11.6 million have been in Japan.
3. According to documents prepared by FDA reviewers, 12 Japanese children, ages 1 to 16, have died after taking Tamiflu. Six of these children, ages 2 to 4, were completely healthy before getting the flu. In the words of the FDA reviewers, “it is concerning that six young patients died suddenly within one to two days after initiation of oseltamivir therapy.”
4. Also according to the FDA reviewers, there have been 32 reported instances of “neuropsychiatric events” worldwide, with 31 of them occuring in Japan. These neuropsychiatric events include delirium, abnormal behaviour, and hallucinations.
5. Two Japanese boys, ages 12 and 13, jumped from the second story windows of their homes after receiving two doses of Tamiflu.
6. Two Japanese teenagers who died after receiving Tamiflu are thought to have committed suicide.
7. An 8 year old Japanese boy had a frightening hallucination three hours after receiving his first dose of Tamiflu and rushed into the street outside of his house.
8. There have been multiple reports of severe skin reactions in adults and children all over the world who have taken Tamiflu.
Predictably, Roche has responded to this data by saying that “the reports of these problems were rare given that millions of people had used the drug, and that the problems might have been caused by the flu itself.”
Roche has also said that “the death rate among children taking Tamiflu was only one in a million and that the rate of death and other problems was no greater than in children with the flu who did not take the drug.”
If this is in fact true, then why take the drug in the first place? If the rates of death for children who take Tamiflu and children who don’t take it are the same, why take Tamiflu at all?
Sorry for the cliche, but no amount of money in this world could persuade me to take Tamiflu or any other flu drug or vaccine. And you better believe that I’d do everything I possibly could to make sure that my own child is never exposed to such drugs. It amazes and saddens me to know that so many children and adults all over the world take drugs like Tamiflu thinking that they are perfectly safe and that they are doing something good for their health.
Click here to read the original article in The New York Times. Registration is required.
“In 2005, the Bush Administration dedicated 7.1 billion dollars to the development of an emergency pandemic response strategy. No matter how much money is invested in protecting us from an outbreak of avian flu or some other epidemic, the immune system is our first and last line of defense.”
These are the things we all value, and they are just a fewof the terms we associate with an immune system that works, an immune response that’s never late and doesn’t misfire, a state of immune-readiness constantly prepared to wage a balanced and accurate defense against bodily intruders like germs that make us sick, bacteria that give us infection, and viruses that kill.
It’s a hostile world. No matter who we are, where we live, or what we do, the immune system is our first and last line of defense. No matter the money governments around the world spend on pandemic response strategies. No matter the alleged availability or potency of antibiotics. No matter the research dollars pouring into vaccine development. At the end of the day, one question rises above the rest: How strong is your immune system?
Immune System Basics
Your immune system has three primary functions: first to recognize bodily intruders, second to wage an effective attack, and third to remember invaders when they return.
Although this may not be “news,” what hasn’t been widely reported is that a molecule called transfer factor (TF) is responsible for storing the information our immune system uses to perform these functions.
Transfer Factor = Immune System “Intelligence”
Transfer factor isn’t a vitamin, mineral, or herb, but a molecule that forms the core of your immune system’s intelligence network by storing information about previous immune system encounters with bacteria, viruses and the like.
However, studies indicate that transfer factor does much more than simply “remember” our immune system experiences. It also provides strategic information about how to best handle the pathogens we encounter by stimulating NK (natural killer) cell activity.
Similar to the genetic code stored in the DNA molecule, the transfer factor molecule provides your immune system with the information it needs to:
1. Identify a problem,
2. Balance your body’s response, and
3. Accelerate positive immune functioning.
Transfer Factor Its History, and Why You Haven’t Heard About It
While studying Tuberculosis in 1949, Dr. H. Sherwood Lawrence (prior Head of Infectious Diseases and Immunology of New York University, 1959—2000) discovered that he could “transfer” a positive immune response from a recovered donor to a naive recipient, someone who had never encountered tuberculosis.
At the time, Lawrence used white blood cells as the source of transfer factor from human donors to lucky patients via intravenous administration. Although transfer factor was hailed as a major discovery by researchers and scientists around the world, penicillin took center stage as Western medicine’s panacea, a “cure-all” to sickness and infection.
No one can argue the role antibiotics have played in battling disease. At the same time, more professionals than ever are concerned about their effectivenes as germs get smarter. Antibiotics replace the immune system, rather than strengthen it. For this reason, people are looking for alternative waysto support and promote their immune response.
Since Lawrence’s ground-breaking life work, thousands of scientific studies have explored the effectiveness of the immune system molecule, transfer factor. And over the last twenty years, three major immunological discoveries have revolutionized transfer factor science:
In the early days of transfer factor therapy, donors were human, and transfer factor was received via injection. It wasn’t until the 1980s that medical science discovered the efficacy and compatibility ofanimal-sourced transfer factor. Today, we know that unlike antibodies, transfer factor is cross-species compatible. This means that its benefit is universal. As a result, we can profit from the transfer factor of animals with heroic (resilient) immune systems.
• Oral Consumption: Delivery
Transfer factor science has come a long way since its intravenous beginning. In the 1980s, it was discovered that transfer factor is orally transmissible, which makes sense because it’s passed from mother to child through colostrum, a mother’s first milk. A wide range of studies conducted over the past two decades now underscore the efficacy of orally consumed transfer factor.
• Technology
Scientists have only recently developed the techniques needed to extract and concentrate transfer factor molecules for optimal potency. For example, although traces of transfer factor exist in colostrum, they must be isolated and purified for ideal results.
Heroic Immune Systems = Potent Transfer Factor
The most potent transfer factor molecules come from “heroic” immune systems that have had previous encounters with a wide range of viral and bacterial strains. Today’s scientific community is particularly interested in two sources of transfer factor: one derived from cows, the other from chickens. Cow colostrum contains potent transfer factor designed to prepare the newborn calf for the barnyard’s toxic environment.
Similarly, eggs offer another source for harvesting potent transfer factor strains.
Our Daily Need for Transfer factor
Hundreds of thousands of people around the world take transfer factor on a daily basis for increased immune system support. In fact, one report indicates that in China, “more than six million people have used transfer factor as a prophylaxis for hepatitis.”
Throughout the world, people are discovering that transfer factor offers general immune maintenance for our on-the-go lifestyles. This may be why the popular book, The Cerm Survival Guide, by Dr. Kenneth A. Bock, M.D., et al., lists six Transfer Factor capsules per day as “essential” when traveling.
Reported Benefits of Transfer Factor
Transfer factor is referred to as an “immunocorrector” and reportedly supports immune function in different ways, including the suppression of an over-active immune system for autoimmune disorders as well as the stimulation of normal immune functioning.
In May of 2000, Alternative Medicine magazine published an article titled “Educating the Immune” in which DJ. Fletcher writes that “the immune system is one of the miracles of nature, and Transfer Factor (TF), a type of immune therapy, is part of that miracle.” Transfer factor, Fletcher states, may contribute to positive immune function for people with “Candida albicans, Epstein-Barr, HIV, and other health conditions, including Chronic Fatigue Syndrome, Fibromyalgia, and Hepatitis.”
As a “smart molecule” and immune system balancer, transfer factor has proven valuable in helping the immune system suppress unhealthy and potentially destructive levels of inflammation. In fact, transfer factor actually educates your immune
system to what it must know for optimal performance when ever inflammation occurs.
Transfer Factor Science: Breakthrough and Discovery
Countless research articles explore the role transfer factor molecules play in proper immune system functioning, and there have been (and continue to be) substantial efforts to capitalize on this research by securing intellectual rights for transfer factor processes. For example, 4Life Research, LLC, of Sandy, Utah, has conducted numerous scientific studies and has multiple patents.
• In one independent NK Cell Study, 4Life’s combination of bovine and avian sourced transfer factor dramatically increased natural killer cell activity four hundred thirty-seven percent above baseline.
• In October of 2002, 4Life patented methods for “obtaining transfer factor from avian sources” as well as new ways of generating and preparing the non-mammalian transfer factor.”
• In March of 2005, 4Life patented a process of combining transfer factor “from at least two different types of source animals.”
4Life Research’s CEO, David Lisonbee, has been at the forefront of immune research for more than 12 years. For his contribution to the search for “new natural immunocorrectors, new sources of extraction, and progressive developmental technologies,” Lisonbee will be inducted into the Russian Academy of Medical & Technical Sciences and receive the 2006 I.N. Blokhina Award for Bio-Technological Advancement during the last week of February.
As noted above, transfer factor is the subject of many publications. In addition to the ones cited earlier, a book, Transfer Factors: Maximize Your Immune IQ, authored by David Lisonbee and Dr. William Hennen, is scheduled for release this March. The book will address the importance of transfer factor and proper immune system functioning in today’s world.
Transfer Factor Today
In 2005, the Bush Administration dedicated 7.1 billion dollars to the development of an emergency pandemic response strategy.
No matter how much money is invested in protecting us from an outbreak of avian flu or some other epidemic, the immune system is our first and last line of defense.
Its worth is invaluable, because without an immune system, we face pestilence, disease, infirmity and death.
Fortunately, scientific research continues to reveal a very promising link between the transfer factor molecule and optimal immune response.
•For references: Send a SASE to totalhealth magazine.
The swine flu, now H1N1 virus is spreading in distinct regions of the globe. But the WHO says the pandemic is only ‘moderate in severity’ and cautions against overreaction by the public.
By Thomas H. Maugh II
10:21 AM PDT, June 11, 2009
The World Health Organization this morning acknowledged what many health experts have been saying for weeks: The outbreak of novel H1N1 virus is now a pandemic.
In a letter sent to its member countries, the WHO said it is officially raising its infectious diseases alert to Phase 6, its highest level, in recognition of the fact that the virus is now undergoing communitywide transmission in Australia as well as in North America. Such spread in two distinct regions of the world is the primary criterion for raising the alert level.
FOR THE RECORD:An earlier version of this article said emergency rooms in Chile had been overrun by people fearful that they had contracted the swine flu virus. Actually, emergency rooms in Argentina, not Chile, reported this trend. But the agency said that the pandemic is only “moderate in severity” and cautioned against overreactions to the increased alert level.
The announcement marks the advent of the first global influenza epidemic in 41 years. The last one was the Hong Kong flu epidemic of 1968, which killed an estimated 1 million people worldwide.
So far, the H1N1 or swine flu pandemic this year has accounted for 27,737 laboratory-confirmed cases and 141 deaths, although health officials believe many times that number have been infected but have not been tested because their disease was mild.
A normal seasonal flu outbreak kills about 250,000 to 500,000 people worldwide.
In most industrialized countries, the rise in the alert level will have little practical effect because health authorities were already behaving as though a pandemic had been declared. In the United States, where there have been more than 13,000 cases and at least 27 deaths, “Our actions in the past month have been as if there was a pandemic in this country,” said Glen Nowak, a spokesman for the Centers for Disease Control and Prevention.
But it will accelerate the production of a vaccine against the new virus. Several countries have signed contracts for the vaccine with manufacturers that call for its production if a pandemic is declared. Most of them have received so-called seed stock viruses from the CDC in the past two weeks, allowing them to begin the lengthy process of growing the virus in eggs and producing vaccines. But it will still take a minimum of four to six months for the vaccines to be available for use.
The announcement will have more impact on Third World countries, freeing up additional funds for treatment and prevention and helping to make stocks of antiviral drugs more readily available.
The WHO has hesitated to raise the alert level for fear that such an announcement would be misconstrued as an indication that the virus has become more pathogenic. WHO spokesman Gregory Hartl emphasized today that “Phase 6 doesn’t mean anything concerning severity, it is concerning global spread. . . . Pandemic means global, but it doesn’t have any connotation of severity or mildness.”
In fact, he said, all evidence to date is overwhelming that the virus is mild in its effects. Experts fear, however, that as it passes through populations, it could mutate to become more lethal and return with increased force in the winter influenza season. That is what happened with the Spanish flu pandemic of 1918.
Officials had said they feared that the announcement would lead frightened people who are not really sick to overrun hospital emergency rooms, impairing the healthcare system’s ability to treat the truly sick. That has happened in past outbreaks, and there is already some evidence that it is happening in South America, particularly in Argentina, where the numbers of infected have been growing.
Dr. Keiji Fukuda, assistant director general of the WHO, also said earlier this week that he fears imposition of travel restrictions, border closing and bans on food imports — all of which have already happened in the earlier stages of the outbreak.
We already knew the power of immune system over disease, but many won’t believe it. Check out the Transferceutical Company 4Life Research Inc.
By MARILYNN MARCHIONE, AP Medical Writer – Sun May 31, 9:19 AM PDT
ORLANDO, Fla. – First there was surgery, then chemotherapy and radiation. Now, doctors have overcome 30 years of false starts and found success with a fourth way to fight cancer: using the body’s natural defender, the immune system.
Wednesday May 27, 2009 photo, Dr. Patrick Hwu, left, talks with his cancer patient Hilde Stapleton during an examination at The University of Texas MD Anderson Cancer Center in Houston. Stapleton has been receiving an experimental treatment for melanoma. (AP Photo/David J. Phillip)
The approach is called a cancer vaccine, although it treats the disease rather than prevents it.
At a cancer conference Sunday, researchers said one such vaccine kept a common form of lymphoma from worsening for more than a year. That’s huge in this field, where progress is glacial and success with a new treatment is often measured in weeks or even days.
Experimental vaccines against three other cancers ? prostate, the deadly skin diseasemelanoma and an often fatal childhood tumor called neuroblastoma ? also gave positive results in late-stage testing in recent weeks, after decades of struggles in the lab.
“I don’t know what we did differently to make the breakthrough,” said Dr. Len Lichtenfeld of the American Cancer Society.
Instead of a single “A-Ha!” moment, there have been many “ah, so” discoveries about the immune system that now seem to be paying off, said Dr. John Niederhuber, director of the National Cancer Institute.
It’s way too soon to declare victory. No one knows how long the benefits will last, whether people will need “boosters” to keep their disease in check, or whether vaccines will ever be a cure. Many vaccines must be custom-made for each patient. How practical will that be, and what will it cost?
Those are all good questions ? but there are no answers yet, said Dr. Richard Schilsky, a University of Chicago cancer specialist who is president of theAmerican Society of Clinical Oncology.
Several vaccine studies were reported over the weekend at the oncology group’s annual meeting in Florida.
A big problem has been getting the immune system to “see” cancer as a threat, said Dr. Patrick Hwu, melanoma chief at the University of Texas M.D. Anderson Cancer Center. Viruses like the flu or polio are easily spotted by the immune system because they look different from human cells.
“But cancer comes from our own cells. And so it’s more like guerrilla warfare ? the immune system has trouble distinguishing the normal cells from the cancer cells,” he said.
To help it do that, many cancer vaccines take a substance from a cancer cell’s surface and attach it to something the immune system already recognizes as foreign ? in the lymphoma vaccine’s case, a shellfish protein.
“It’s a mimic to what you’re trying to kill, a training device to train the immune system to kill something,” Hwu explained.
To make the attack as strong as possible, doctors add a substance to put the immune system on high alert.
Dr. Stephen Schuster of the University of Pennsylvania School of Medicine led a study testing BiovaxID, an experimental vaccine against follicular lymphoma developed by the National Cancer Institute. Rights to it are now held by Biovest International Inc. of Worcester, Mass., and some of his co-researchers have financial ties to the company.
To be in the study, patients had to have achieved a remission for at least six months with standard chemo. This often occurs with this type of lymphoma, but the disease usually comes back.
Researchers gave 41 patients the shellfish protein and an immune booster; 76 other patients were given those plus the vaccine. After nearly five years of followup, the average time until the cancer worsened was 44 months in the vaccine group and 30 months in the others.
Big gains also were seen with a neuroblastoma vaccine developed by the cancer institute. In a study of 226 patients, 86 percent of vaccine recipients were still alive after two years versus 75 percent of others not given the vaccine. Results were released by the oncology society two weeks ago.
The benefits from a melanoma vaccine developed by the cancer institute were more modest. It extended the time until patients relapsed ? three months versus one and a half for those not given the vaccine.
Hilde Stapleton, 53, of suburban Houston, is one of the lucky ones it helped. Still, she found what many other vaccine recipients have learned: The vaccine had few side effects, but the immune system boosters were “like the worst case of flu you’ve ever had,” she said.
The prostate cancer vaccine, Provenge, is farthest along. Its maker, Seattle-based Dendreon Corp., is seeking federal Food and Drug Administration approval for it. A study last month found that it extended survival by four months in men with very advanced disease.
Doctors unconnected with these experiments are cautiously optimistic.
“We’ve raised so many false hopes in the past,” said Lichtenfeld of the Cancer Society. “What’s different this time is we have the science reports to back up improvements.”
“
